Merck Automates MS-Based Workflows to Accelerate ADC Discovery

Identifying the most promising Antibody Drug Conjugates (ADCs) requires in-depth candidate characterization using a wide range of analytical techniques, including mass spectrometry (MS), to evaluate multiple critical quality attributes (CQAs). At Merck, MS-based experiments generated large volumes of data across global sites, making it difficult for scientists to detect and investigate deviations that affect ADC quality.  

In this case study, learn how Merck uses the Genedata Biopharma Platform, leveraging Genedata Biologics® and Genedata Expressionist®, to build a structured, data-rich environment that centralizes multi-source data and provides scientists with immediate access to analysis-ready information throughout ADC discovery. By automating previously manual MS-based workflows, improving access to product characterization data, and supporting AI-driven analytics, Merck accelerates decision-making and efficiently advances the most promising ADC candidates.